Dr. Guillian Ajami Orino

02/08/2026

Book your consultation today!

02/08/2026

02/08/2026

07/07/2026

Book your consultation today! 💖

05/07/2026

We're always committed to help you achieve your health goals.
📍 Medical Consultation
⚖️ Weight Loss Management
💉 Vaccinations

Book your consultation today! 💖

23/05/2026

💡 JAMA Insights: receptor agonists and dual incretin agents support weight loss by reducing appetite and energy intake.

While intensive lifestyle intervention enhances outcomes with older medications, new evidence suggests greater weight loss from incretin-based therapies can be attained with only modest behavioral support.

Current best practices recommend individualized diet and physical activity counseling to address side effects, preserve lean mass, and encourage healthy, sustainable habits for patients with using these therapies.

https://ja.ma/4ftW1cj

23/05/2026

Consult na!

Patients with obesity who were treated with GLP-1 receptor agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists had a lower overall cancer risk and a lower risk for skin cancer than untreated patients.

“In this large cohort study, GLP-1 and GLP-1/GIP use was associated with a significant reduction in the overall cancer risk and in skin cancers, with no significant differences in gastrointestinal cancers, pancreatic cancers, as well as hepatobiliary cancers,” the authors of the study wrote. https://mdsc.pe/4fAUzVC

28/04/2026

A result of 6 months of medically supervised GLP-1 + GIP shots.

Approved as a treatment for chronic weight management by helping control appetite, making you feel full longer, as well as improving how the body regulates blood sugar.

Individual results may vary per person based on their diet and lifestyle.

If you’re ready to take the next step in your weight loss journey, send us a message for proper evaluation.